BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 27244218)

  • 1. Increased incidence of FBXW7 and POLE proofreading domain mutations in young adult colorectal cancers.
    Kothari N; Teer JK; Abbott AM; Srikumar T; Zhang Y; Yoder SJ; Brohl AS; Kim RD; Reed DR; Shibata D
    Cancer; 2016 Sep; 122(18):2828-35. PubMed ID: 27244218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FBXW7 mutation analysis and its correlation with clinicopathological features and prognosis in colorectal cancer patients.
    Chang CC; Lin HH; Lin JK; Lin CC; Lan YT; Wang HS; Yang SH; Chen WS; Lin TC; Jiang JK; Chang SC
    Int J Biol Markers; 2015 Feb; 30(1):e88-95. PubMed ID: 25450649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of FBXW7, a cell cycle regulating gene, in colorectal cancer: clinical significance.
    Iwatsuki M; Mimori K; Ishii H; Yokobori T; Takatsuno Y; Sato T; Toh H; Onoyama I; Nakayama KI; Baba H; Mori M
    Int J Cancer; 2010 Apr; 126(8):1828-1837. PubMed ID: 19739118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations.
    Hussein YR; Weigelt B; Levine DA; Schoolmeester JK; Dao LN; Balzer BL; Liles G; Karlan B; Köbel M; Lee CH; Soslow RA
    Mod Pathol; 2015 Apr; 28(4):505-14. PubMed ID: 25394778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.
    Domingo E; Freeman-Mills L; Rayner E; Glaire M; Briggs S; Vermeulen L; Fessler E; Medema JP; Boot A; Morreau H; van Wezel T; Liefers GJ; Lothe RA; Danielsen SA; Sveen A; Nesbakken A; Zlobec I; Lugli A; Koelzer VH; Berger MD; Castellví-Bel S; Muñoz J; ; de Bruyn M; Nijman HW; Novelli M; Lawson K; Oukrif D; Frangou E; Dutton P; Tejpar S; Delorenzi M; Kerr R; Kerr D; Tomlinson I; Church DN
    Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):207-216. PubMed ID: 28404093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plk2 promotes tumor growth and inhibits apoptosis by targeting Fbxw7/Cyclin E in colorectal cancer.
    Ou B; Zhao J; Guan S; Wangpu X; Zhu C; Zong Y; Ma J; Sun J; Zheng M; Feng H; Lu A
    Cancer Lett; 2016 Oct; 380(2):457-466. PubMed ID: 27423313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of molecular targets in vulvar cancers.
    Palisoul ML; Mullen MM; Feldman R; Thaker PH
    Gynecol Oncol; 2017 Aug; 146(2):305-313. PubMed ID: 28536037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and epigenetic features of colorectal cancer patients with somatic POLE proofreading mutations.
    Kawai T; Nyuya A; Mori Y; Tanaka T; Tanioka H; Yasui K; Toshima T; Taniguchi F; Shigeyasu K; Umeda Y; Fujiwara T; Okawaki M; Yamaguchi Y; Goel A; Nagasaka T
    Clin Epigenetics; 2021 May; 13(1):117. PubMed ID: 34034807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Less frequently mutated genes in colorectal cancer: evidences from next-generation sequencing of 653 routine cases.
    Malapelle U; Pisapia P; Sgariglia R; Vigliar E; Biglietto M; Carlomagno C; Giuffrè G; Bellevicine C; Troncone G
    J Clin Pathol; 2016 Sep; 69(9):767-71. PubMed ID: 26797410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathogenomic analysis of mismatch repair proficient colorectal adenocarcinoma uncovers novel prognostic subgroups with differing patterns of genetic evolution.
    Braxton DR; Zhang R; Morrissette JD; Loaiza-Bonilla A; Furth EE
    Int J Cancer; 2016 Oct; 139(7):1546-56. PubMed ID: 27194209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathologic characteristics of FBXW7-mutated colorectal adenocarcinoma and association with aberrant beta-catenin localization.
    Escobar D; Bushara O; Sun L; Liao J; Yang GY
    Hum Pathol; 2022 Jan; 119():51-58. PubMed ID: 34717891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fbxw7 hotspot mutations and human colon cancer: mechanistic insights from new mouse models.
    Grim JE
    Gut; 2014 May; 63(5):707-9. PubMed ID: 24000292
    [No Abstract]   [Full Text] [Related]  

  • 13. Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response.
    Temko D; Van Gool IC; Rayner E; Glaire M; Makino S; Brown M; Chegwidden L; Palles C; Depreeuw J; Beggs A; Stathopoulou C; Mason J; Baker AM; Williams M; Cerundolo V; Rei M; Taylor JC; Schuh A; Ahmed A; Amant F; Lambrechts D; Smit VT; Bosse T; Graham TA; Church DN; Tomlinson I
    J Pathol; 2018 Jul; 245(3):283-296. PubMed ID: 29604063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FBXW7-mutated colorectal cancer cells exhibit aberrant expression of phosphorylated-p53 at Serine-15.
    Li N; Lorenzi F; Kalakouti E; Normatova M; Babaei-Jadidi R; Tomlinson I; Nateri AS
    Oncotarget; 2015 Apr; 6(11):9240-56. PubMed ID: 25860929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation.
    Tong J; Tan S; Zou F; Yu J; Zhang L
    Oncogene; 2017 Feb; 36(6):787-796. PubMed ID: 27399335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in POLE and survival of colorectal cancer patients--link to disease stage and treatment.
    Stenzinger A; Pfarr N; Endris V; Penzel R; Jansen L; Wolf T; Herpel E; Warth A; Klauschen F; Kloor M; Roth W; Bläker H; Chang-Claude J; Brenner H; Hoffmeister M; Weichert W
    Cancer Med; 2014 Dec; 3(6):1527-38. PubMed ID: 25124163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. POLE somatic mutations in advanced colorectal cancer.
    Guerra J; Pinto C; Pinto D; Pinheiro M; Silva R; Peixoto A; Rocha P; Veiga I; Santos C; Santos R; Cabreira V; Lopes P; Henrique R; Teixeira MR
    Cancer Med; 2017 Dec; 6(12):2966-2971. PubMed ID: 29072370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FBXW7 is involved in the acquisition of the malignant phenotype in epithelial ovarian tumors.
    Kitade S; Onoyama I; Kobayashi H; Yagi H; Yoshida S; Kato M; Tsunematsu R; Asanoma K; Sonoda K; Wake N; Hata K; Nakayama KI; Kato K
    Cancer Sci; 2016 Oct; 107(10):1399-1405. PubMed ID: 27486687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TP53, PIK3CA, FBXW7 and KRAS Mutations in Esophageal Cancer Identified by Targeted Sequencing.
    Zheng H; Wang Y; Tang C; Jones L; Ye H; Zhang G; Cao W; Li J; Liu L; Liu Z; Zhang C; Lou F; Liu Z; Li Y; Shi Z; Zhang J; Zhang D; Sun H; Dong H; Dong Z; Guo B; Yan HE; Lu Q; Huang X; Chen SY
    Cancer Genomics Proteomics; 2016; 13(3):231-8. PubMed ID: 27107065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of the atypical FBXW7 mutation spectrum in human tumours by conditional expression of a heterozygous propellor tip missense allele in the mouse intestines.
    Davis H; Lewis A; Behrens A; Tomlinson I
    Gut; 2014 May; 63(5):792-9. PubMed ID: 23676439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.